Reviewing the Power of Health and Wellness Coaching in Multiple Sclerosis Care
August 5th 2025At CMSC 2025, Cassandra Moore, MPH, CPH, associate vice president of strategy and innovation at the National MS Society, discussed the impact of health and wellness coaching in patients with multiple sclerosis.
Alzheimer Vaccine ABvac40 Shows Potential to Slow Cognitive Decline in Phase 2 Study
August 4th 2025Data presented at AAIC 2025 from a phase 2 study suggest that ABvac40 may slow cognitive decline in patients with Alzheimer disease, particularly among those who developed higher antibody levels.
Findings From First Cohort of SPG302 in Phase 2 Alzheimer Disease Trial: Sharron Gargosky, PhD
August 1st 2025The chief development officer at Spinogenix shared initial results from the first cohort of the company’s phase 2 trial assessing SPG302 in Alzheimer disease presented at AAIC 2025. [WATCH TIME: 6 minutes]
Narcolepsy Treatment Trends and Change in Alerting Agent Use After Low-Sodium Oxybate Initiation
July 29th 2025In this final episode, the sleep experts analyze real-world prescribing data to understand how low-sodium oxybate impacts the use of traditional alerting agents in narcolepsy. [WATCH TIME: 4 minutes]